PRKDC and hematologic disorder: Results were recently reported from a first-in-human Phase I study (NCT01353625) in patients with advanced solid (including ovarian) or hematological malignancies for an inhibitor of mTORC1/2 which is also a potent inhibitor of DNA-PK (CC-115), concluding that CC-115 was well-tolerated with toxicities consistent with other mTOR inhibitor treatments, and suggesting that this novel dual mTOR/DNA-PK inhibitor could be a favorable treatment for cancer patients[106].